This trial is testing izokibep, a small protein molecule, as a possible treatment for active non-infectious uveitis, a condition which causes inflammation in the eye.
1 Primary · 9 Secondary · Reporting Duration: Week 10 up to Week 52
Experimental Treatment
Non-Treatment Group
100 Total Participants · 5 Treatment Groups
Primary Treatment: Izokibep · Has Placebo Group · Phase 2
Age 18 - 75 · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Texas | 100.0% |
18 - 65 | 100.0% |
Clinical Research Site | 100.0% |
Met criteria | 100.0% |